Impact of liver metastasis on the efficacy of immune checkpoint inhibitors for advanced colorectal cancer

Key Points

Liver metastasis negatively impacts survival outcomes in advanced colorectal cancer.
Patients with liver metastasis receiving immune checkpoint inhibitors experience reduced prognosis.
Assessment of liver metastasis as a prognostic factor highlights its importance in treatment plans.
Further research is needed to understand the mechanisms affecting immunity in mCRC cases.

Abstract

Liver metastasis is associated with worse survival outcomes in patients with mCRC receiving ICIs. These results suggest that liver metastasis may serve as a negative prognostic factor in the context of immunotherapy for mCRC.

Impact of liver metastasis on the efficacy of immune checkpoint inhibitors for advanced colorectal cancer

Key Points

Abstract

Cite This Study